Avanafil

Pediatric

FDA APPROVAL DATE: 04/27/2012

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alcohol, Alpha blockers, Amprenavir, Antihypertensives, Aprepitant, Atazanavir, Clarithromycin, Diltiazem, Erythromycin, Fluconazole, Fosamprenavir, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Nitrates, Ritonavir, Saquinavir, Strong CYP3A4 inhibitors, Telithromycin, Verapamil

PREGNANCY CATEGORY: C
Not indicated for use in women

Contra-indicated in patients using any form of nitrates.

Our database has 54 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of avanafil in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 08/24/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top